Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:AVTX NASDAQ:ETON NASDAQ:NBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.70+3.2%$20.02$16.65▼$31.26$798.96M0.91823,033 shs459,232 shsAVTXAvalo Therapeutics$13.61-0.9%$15.82$4.06▼$24.27$722.25M0.831.76 million shs1.34 million shsETONEton Pharmaceuticals$28.90+4.7%$27.54$13.09▼$35.66$756.30M0.87394,454 shs721,997 shsNBPI-Mab$1.80+2.9%$2.22$1.63▼$6.79$202.38M1.47739,303 shs277,473 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-1.93%-5.27%-17.30%-11.48%-30.43%AVTXAvalo Therapeutics-1.58%-12.98%+0.22%-21.84%+212.27%ETONEton Pharmaceuticals+0.77%-14.78%-4.46%+60.15%+59.78%NBPI-Mab+2.34%-6.42%-26.47%-51.92%+174,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.70+3.2%$20.02$16.65▼$31.26$798.96M0.91823,033 shs459,232 shsAVTXAvalo Therapeutics$13.61-0.9%$15.82$4.06▼$24.27$722.25M0.831.76 million shs1.34 million shsETONEton Pharmaceuticals$28.90+4.7%$27.54$13.09▼$35.66$756.30M0.87394,454 shs721,997 shsNBPI-Mab$1.80+2.9%$2.22$1.63▼$6.79$202.38M1.47739,303 shs277,473 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-1.93%-5.27%-17.30%-11.48%-30.43%AVTXAvalo Therapeutics-1.58%-12.98%+0.22%-21.84%+212.27%ETONEton Pharmaceuticals+0.77%-14.78%-4.46%+60.15%+59.78%NBPI-Mab+2.34%-6.42%-26.47%-51.92%+174,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.88Reduce$24.0028.34% UpsideAVTXAvalo Therapeutics 2.83Moderate Buy$48.13253.60% UpsideETONEton Pharmaceuticals 2.40Hold$41.0041.87% UpsideNBPI-Mab 2.00Hold$9.00400.00% UpsideCurrent Analyst Ratings BreakdownLatest NBP, AVTX, ETON, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.006/1/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.005/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/14/2026AVTXAvalo Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$62.00 ➝ $55.005/14/2026AVTXAvalo Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $34.005/14/2026AVTXAvalo Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$39.00 ➝ $45.005/14/2026AVTXAvalo Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $35.005/11/2026AVTXAvalo Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$48.00 ➝ $60.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.15$4.39 per share4.26$17.17 per share1.09AVTXAvalo Therapeutics$60K11,924.63N/AN/A$4.49 per share3.03ETONEton Pharmaceuticals$79.95M9.90$0.01 per share5,326.83$0.98 per share29.49NBPI-Mab$3.89M53.51N/AN/A$2.00 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.276.383.5611.00%15.12%7.14%8/6/2026 (Estimated)AVTXAvalo Therapeutics-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%8/6/2026 (Estimated)ETONEton Pharmaceuticals-$4.60M-$0.07N/A15.13N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)NBPI-Mab-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/ALatest NBP, AVTX, ETON, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million5/13/2026Q1 2026AVTXAvalo Therapeutics-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million4/8/2026Q4 2025NBPI-MabN/A-$0.2990N/A-$0.2990N/AN/A3/23/2026Q4 2025AVTXAvalo Therapeutics-$1.54-$0.37+$1.17-$0.37($0.21) million$0.06 million3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ANBPI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82AVTXAvalo TherapeuticsN/A7.667.66ETONEton Pharmaceuticals0.621.210.88NBPI-MabN/A8.098.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AVTXAvalo Therapeutics87.06%ETONEton Pharmaceuticals27.86%NBPI-Mab38.38%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%AVTXAvalo Therapeutics4.46%ETONEton Pharmaceuticals16.49%NBPI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableAVTXAvalo Therapeutics4052.57 million50.22 millionNot OptionableETONEton Pharmaceuticals2027.39 million22.88 millionOptionableNBPI-Mab380115.65 million90.09 millionN/ANBP, AVTX, ETON, and AMPH HeadlinesRecent News About These CompaniesCong Claire Xu Sells 3,494 Shares of I-Mab (NASDAQ:NBP) StockJune 3 at 6:44 AM | insidertrades.comNovaBridge to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comMark Arnold Hagler Buys 230,000 Shares of I-Mab (NASDAQ:NBP) StockApril 29, 2026 | insidertrades.comNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueApril 22, 2026 | globenewswire.comNovaBridge's Givastomig Could Drive A Major Re-RatingApril 9, 2026 | seekingalpha.comNovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateApril 7, 2026 | globenewswire.comNovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerMarch 16, 2026 | globenewswire.comNovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyMarch 9, 2026 | globenewswire.comNovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026March 3, 2026 | globenewswire.comNovaBridge to Present at the Leerink Partners 2026 Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comNovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech PlatformFebruary 19, 2026 | globenewswire.comNovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBP, AVTX, ETON, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$18.70 +0.58 (+3.20%) Closing price 04:00 PM EasternExtended Trading$18.70 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Avalo Therapeutics NASDAQ:AVTX$13.61 -0.13 (-0.95%) Closing price 04:00 PM EasternExtended Trading$13.88 +0.27 (+1.95%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Eton Pharmaceuticals NASDAQ:ETON$28.90 +1.29 (+4.67%) Closing price 04:00 PM EasternExtended Trading$28.94 +0.04 (+0.14%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.I-Mab NASDAQ:NBP$1.80 +0.05 (+2.86%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.83%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
